Editas Medicine Inc (EDIT NASDAQ) stock market data APIs
$1.9609
0.08(4.1%)
as of June 13, 2025
Try our APIs with
free plan!
Editas Medicine Inc Financial Data Overview
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Prev. Close
1.9609
Open
2.0369
High
2.1344
Low
1.9514
52 wk Range
0.9101-6.05
Market Cap
165 M
Shares Outstanding
83 713 K
Revenue
35 837 K
EPS
-0.92
Beta
2.096
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Editas Medicine Inc data using free add-ons & libraries
Get Editas Medicine Inc Fundamental Data
Editas Medicine Inc Fundamental data includes:
- Net Revenue: 35 837 K
- EBITDA: -200 922 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.66
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Editas Medicine Inc News
New
Editas Medicine Reports 58% HBG1/2 Promoter Editing in Non-Human Primates Using High Efficiency tLNP Delivery Method
Editas Medicine reports 58% mean editing in HSCs after single tLNP dose, aiding sickle cell and beta thalassemia treatments. Quiver AI Summary Editas Medicine announced promising new data demonstrat...
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achieveme...
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
It has been about a month since the last earnings report for Editas Medicine (EDIT). Shares have added about 40% in that time frame, outperforming the S&P 500. Will the recent positive trend continue...
1 Stock Down 97% That Could Double, According to Wall Street
Key Points Editas Medicine focuses on developing gene-editing treatments. The struggling biotech recently gave up on its leading pipeline candidate. Even if it matches Wall Street's estimates in the ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
